Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2021 Jan 22;16(1):e0244079. doi: 10.1371/journal.pone.0244079

Improvement of image quality and assessment of respiratory motion for hepatocellular carcinoma with portal vein tumor thrombosis using contrast-enhanced four-dimensional dual-energy computed tomography

Shingo Ohira 1,2,*, Naoyuki Kanayama 1, Kentaro Wada 1, Toshiki Ikawa 1, Takero Hirata 1, Noriko Kishi 1,3, Tsukasa Karino 1, Hayate Washio 1, Yoshihiro Ueda 1, Masayoshi Miyazaki 1, Masahiko Koizumi 2, Teruki Teshima 1
Editor: Dong-Hoon Lee4
PMCID: PMC7822294  PMID: 33481820

Abstract

To assess the objective and subjective image quality, and respiratory motion of hepatocellular carcinoma with portal vein tumor thrombosis (PVTT) using the contrast-enhanced four-dimensional dual-energy computed tomography (CE-4D-DECT). For twelve patients, the virtual monochromatic image (VMI) derived from the CE-4D-DECT with the highest contrast to noise ratio (CNR) was determined as the optimal VMI (O-VMI). To assess the objective and subjective image quality, the CNR and five-point score of the O-VMI were compared to those of the standard VMI at 77 keV (S-VMI). The respiratory motion of the PVTT and diaphragm was measured based on the exhale and inhale phase images. The VMI at 60 keV yielded the highest CNR (4.8 ± 1.4) which was significantly higher (p = 0.02) than that in the S-VMI (3.8 ± 1.2). The overall image quality (4.0 ± 0.6 vs 3.1 ± 0.5) and tumor conspicuity (3.8 ± 0.8 vs 2.8 ± 0.6) of the O-VMI determined by three radiation oncologists was significantly higher (p < 0.01) than that of the S-VMI. The diaphragm motion in the L-R (3.3 ± 2.5 vs 1.2 ± 1.1 mm), A-P (6.7 ± 4.0 vs 1.6 ± 1.3mm) and 3D (8.8 ± 3.5 vs 13.1 ± 4.9 mm) directions were significantly larger (p < 0.05) compared to the tumor motion. The improvement of objective and subjective image quality was achieved in the O-VMI. Because the respiratory motion of the diaphragm was larger than that of the PVTT, we need to be pay attention for localizing target in radiotherapy.

Introduction

Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related deaths in worldwide, and the incidence of portal vein tumor thrombosis (PVTT), which is associated with dismal outcomes (median overall survival of 2.7–4 months), is 30–40% in patients with advanced HCC [13]. The development of radiotherapy technology facilitates the delivery of high doses to tumors with the minimal radiation doses to organs at risk (OARs), and radiotherapy has been increasingly applied to HCC with PVTT. Choi et al. demonstrated the feasibility outcome of the stereotactic body radiotherapy (30–39 Gy in 3 fractions) with the median survival period of eight months [4].

In radiotherapy, an application of four-dimensional computed tomography (4D-CT) is widely utilized to determine the position and respiratory motion of the target as well as OARs. However, the difference in CT numbers (Hounsfield unit, HU) between the liver and portal vein is small, and thus, it is difficult to visualize the HCC with PVTT clearly with the conventional 4D-CT. To overcome this problem, a methodology of contrast-enhanced 4D-CT (CE-4D-CT) was presented, and it could allow both enhancement of liver tumor contrast and coverage over the entire breathing cycle [5]. The CE-4D-CT has the potential for improving the accuracy of tumor contouring and localization.

Recently, dual-energy CT (DECT) has been increasingly introduced in clinical practice. By using high- and low-energy X rays, the DECT can reconstruct virtual monochromatic images (VMI) at different energy levels ranging 40–140 keV [6, 7]. Husarik et al. demonstrated a value of DECT (low image noise, high contrast-to-noise ratio (CNR), and high lesion conspicuity) for imaging of both hyperattenuating and hypoattenuating liver lesions [8]. Therefore, the CE-4D-CT using the DECT (CE-4D-DECT) has potential for improving the image quality of HCC with PVTT, and for measuring the respiration motion.

This study aimed to assess the objective and subjective image quality of the CE-4D-DECT for the HCC with PVTT for radiotherapy treatment planning. Further, the respiration motion of the PVTT was assessed and its motion was compared with that of the diaphragm.

Materials and methods

Acquisition of CE-4D-DECT

This study was approved by the Institutional Review Board of the Osaka International Cancer Institute (No. 18276), and written informed consent was waived because of the retrospective design. The CE-4D-DECT was performed for twelve patients (ten males and two females; age, 65 years (range, 48–78 years)) for radiotherapy treatment planning. In accordance with the Liver Cancer Study Group of Japan, each PVTT was classified into four categories [9]. Ten patients had PVTT with portal invasion at the first portal branch (Vp3), and two patients had PVTT with portal invasion at the main portal branch (Vp4).

Before simulation, patients’ food or water intake was constrained to avoid unexpected displacement of PVTT due to a bulky stomach. The vacuum cushion was used for patient immobilization, and except for one case, a thermoplastic mold was mounted on the chest and abdomen to prevent a patient from breathing deeply. Thirty milliliters of water containing 5 ml of oral contrast medium was ingested, and a contrast agent (600 mgI/kg body weight) was injected in 30 s using a power injector.

The details of the acquisition technique of the CE-4D-DECT was presented in our previous study [10], and all CT images were acquired using a DECT scanner (Revolution HD, GE Medical Systems, Waukesha, WI) [11]. Briefly, the images of center of PVTT were acquired after 40–80 s from the injection, and the scan delay was changed depending on the location of the tumor, patient’s breathing cycle. All images were acquired in cine mode, and the cine duration time was set approximately 1 s longer than the patient’s respiratory period. The Realtime Position Management system (Varian Medical Systems, Palo Alto, CA) was used to record the patient’s respiratory waveform (free breathing) during the image acquisition. The tube voltage of 140/80 kVp, tube current of 360 mA, gantry rotation time of 0.5 s, and beam collimation of 40 mm was used for the image acquisition. The acquired data were reconstructed with a 2.5-mm slice thickness, a 512 × 512 matrix and a 500-mm field of view.

Data analysis

The image data were transferred to a workstation (Advantage Sim, GE Medical Systems), and the end-exhale and end-inhale respiratory phase image sets were reconstructed using the patient’s respiratory waveform. In the exhale phase image derived from the CE-4D-DECT in each patient, a circular or elliptic region of interest (ROI) was placed in the portal vein, tumor, aorta, liver, erector muscle of spine. For each ROI, the mean and standard deviation (SD) of the HU values were measured the VMIs at various energy levels in the range from 40keV to 140 keV, in 5 keV increments. The SD was determined as the image noise in the ROI. To evaluate the objective image quality of the VMI, the lesion contrast (LC) and the CNR between the portal vein and tumor were calculated using the following formulae:

LC[HU]=CTnumberinROIportalveinCTnumberinROItumor. (1)
CNR=LC(ImagenoiseinROIportalvein)2+(ImagenoiseinROItumor)2. (2)

The optimal VMI (O-VMI) for PVTT delineation for radiotherapy treatment planning was determined as the VMI, which has the highest CNR. The objective image characteristics of the O-VMI were compared with those of the standard VMI (S-VMI) at 77 keV, which shows equivalent HU values with the conventional single-energy CT images (120kVp) [12].

Subsequently, three radiation oncologists assessed the subjective image quality of the S-VMI and O-VMI with respect to the overall image quality and tumor conspicuity. Images were presented to the observers with the window width of 320 HU and window level of 30 HU to score the subjective image quality using the five-point scales (1, very poor; 2, Poor; 3, Satisfactory; 4, Good; 5, Very good). The observers determined the score from the viewpoint of contouring of the gross tumor volume (GTV) and/or OARs.

Using a treatment planning system (Eclipse, Varian Medical Systems), the respiratory motion of the tumor and diaphragm was assessed based on the O-VMIs at exhale and inhale phase (Fig 1). The tumor motion was determined as the difference in the position of the center of the GTV delineated by radiation oncologists between the two images in the left-right (L-R), anterior-posterior (A-P), and superior-inferior (S-I) directions, respectively. Radiation oncologists determined the GTV as the PVTT alone or PVTT combined with the primary tumor. The 3D motion was calculated as the root-mean-square of the tumor motion in the three directions. The diaphragm motion was determined as the difference in the position of the top of the liver dome delineated by a medical physicist between the two images in the three directions, and the 3D motion was also calculated.

Fig 1. Displacement in tumor and diaphragm positions between exhale and inhale phase images.

Fig 1

The paired Wilcoxon signed-rank test (IBM SPSS Statistics version 24; IBM, Armonk, NY, USA) was used to measure the difference in objective and subjective analysis, and respiratory motion. A p value of <0.05 was considered to indicate statistical significance.

Results

Fig 2 shows the CT numbers and image noise in the portal vein and tumor, and the corresponding CNR at different energy levels. The higher HU values were observed in the low energy level of the VMI for both portal vein and tumor, and difference in the HU values between the VMI at low (40 keV) and high (140 keV) energy level was larger in the portal vein than that in the tumor (Fig 2A). The image noise was also larger at the low energy level on the VMI (Fig 2B). The resultant CNR was highest in the VMI at 60 keV, and thus, the image was determined as the O-VMI in this study (Fig 2C).

Fig 2.

Fig 2

Quantitative spectral analysis of virtual monochromatic images at different energy levels; (a) the mean CT number and (b) image noise of the region of interest, and (c) contrast-to-noise ratio between portal vein and tumor. The error bar indicates the standard deviation.

Fig 3 compares the objective quantitative values of the S-VMI with those of O-VMI. The HU values of the aorta (258.8 ± 113.8 HU), liver (113.8 ± 30.2 HU), muscle (59.8 ± 7.5 HU), portal vein (225.4 ± 49.8 HU), and tumor (79.8 ± 30.2 HU) in the O-VMI were significantly higher (p = 0.002) than the corresponding values in the S-VMI (158.7 ± 63.5, 86.5 ± 18.9, 53.1 ± 5.2, 141.1 ± 28.3, and 56.7 ± 18.8 HU for the aorta, liver, muscle, portal vein and tumor, respectively). In contrast, the HU value of the fat in the O-VMI (-97.7 ± 18.3 HU) was significantly lower (p = 0.002) than that in the S-VMI (-84.5 ± 13.4 HU). The O-VMI demonstrated the superiority of the objective image quality over the S-VMI, showing significantly higher LC (134.9 ± 43.6 HU vs 79.1 ± 26.2 HU, p = 0.002) and CNR (4.8 ± 1.4 vs 3.8 ± 1.2, p = 0.002). Fig 4 depicts the S-VMI and O-VMI for patient #3, 4, 6, and 7 in the axial and coronal view point. O-VMI provided better tumor conspicuity than the S-VMI, resulting in higher CRN for each patient (O-VMI vs S-VMI: 3.6 vs 5.0, 4.1 vs 4.8, 5.49 vs 7.4, and 3.8 vs 5.0 for patient #3, 4, 6, and 7, respectively.).

Fig 3. Comparison of objective image quality between Standard Virtual Monochromatic Images (S-VMI, 77 keV) and optimal VMI (O-VMI, 60 keV).

Fig 3

Boxes, median value and upper and lower quartiles; Whiskers, maximum and minimum values within 1.5 × inter-quartile range; Dots, outliers.

Fig 4. Comparison of Standard Virtual Monochromatic Images (S-VMI) at 77 keV and optimal VMI (O-VMI) at 60 keV for patient #3, 4, 6, and 7.

Fig 4

Arrows indicate the portal vein tumor thrombosis.

Table 1 summarizes the subjective image quality determined by three observers. Regarding the overall image quality, the O-VMI provided a significantly higher (p = 0.003) score (4.0 ± 0.6) than that in the S-VMI (3.1 ± 0.5). As in the tumor conspicuity, the mean score in the O-VMI was significantly higher (p = 0.003) than the corresponding value in the S-VMI (3.8 ± 0.8 and 2.8 ± 0.6 for O-VMI and S-VMI, respectively).

Table 1. Subjective image quality expressed as five-point sores.

Patient # Overall image quality Tumor conspicuity
Observer 1 Observer 2 Observer 3 Observer 1 Observer 2 Observer 3
S-VMI O-VMI S-VMI O-VMI S-VMI O-VMI S-VMI O-VMI S-VMI O-VMI S-VMI O-VMI
1 3 4 3 4 2 3 3 4 2 3 2 3
2 3 3 3 3 2 3 3 3 1 3 2 2
3 3 4 4 4 3 4 3 4 3 4 3 4
4 3 4 3 4 3 4 3 4 3 5 3 4
5 3 4 3 3 3 4 3 4 2 4 3 4
6 3 4 4 5 4 4 3 4 3 4 4 4
7 3 4 3 5 3 5 3 4 3 4 3 4
8 3 4 3 5 2 4 3 4 3 5 3 4
9 3 4 4 5 4 4 3 4 4 5 3 4
10 4 4 4 5 3 4 3 4 3 5 3 4
11 3 4 3 4 3 4 2 3 3 3 2 3
12 3 3 3 4 4 3 3 4 2 2 3 2
Mean 3.1 3.8 3.3 4.3 3.0 3.8 2.9 3.8 2.7 3.9 2.8 3.5
SD 0.3 0.4 0.5 0.8 0.7 0.6 0.3 0.4 0.8 1.0 0.6 0.8
Overall mean (S-VMI vs O-VMI) 3.1 vs 4.0 2.8 vs 3.8
p-value 0.003 0.003

The individual respiratory motion between the tumor and diaphragm are directly compared in Fig 5. The diaphragm motion in the L-R (3.3 ± 2.5 mm, p = 0.02) and A-P (6.7 ± 4.0 mm, p = 0.004) directions were significantly larger compared to the tumor motion (1.2 ± 1.1 mm and 1.6 ± 1.3 mm in the L-R and A-P direction, respectively). The respiratory motion of the tumor (8.4 ± 3.6 mm) and diaphragm (10.1 ± 3.9 mm) were comparable in the S-I direction (p = 0.3). Consequently, the 3D motion of the diaphragm (13.1 ± 4.9 mm, p = 0.03) was significantly larger than the tumor motion (8.8 ± 3.5 mm).

Fig 5. Distribution of respiratory motion of tumor (horizontal axis) and diaphragm (vertical axis) for individual patients.

Fig 5

Discussion

In this study, we demonstrated the superiority of O-VMI (60 keV) over S-VMI (77 keV) in regard to the objective image quality, expressed as the CNR. Further, radiation oncologists judged that the O-VMI provided better overall image quality as well as tumor conspicuity.

Historically, the role of radiotherapy for the management of HCC has been limited due to the low radiation tolerance of the liver tissue. Kim et al. reported that the total liver volume receiving ≥ 30 Gy appears to be a useful dose–volumetric parameter for predicting the risk of Grade 2 (or worse) radiation-induced liver toxicity (RILT), and this volume should be limited to ≤ 60% whenever possible [13]. Dawson observed the 19 RILT among 203 patients who underwent liver irradiation, and no cases of RILT were observed when the mean liver dose was < 31 Gy [14]. Because of the better information regarding RILT, innovative RT technologies including intensity modulated radiotherapy, SBRT, particle therapy, and improvement in the precision of dose delivery with image-guided radiotherapy, radiotherapy has become an accepted tool in the management of HCC [1]. Shui et al. applied SBRT for 70 patients with PVTT, and the thrombus shrinkage and portal vein flow restoration could be achieved in the majority of cases [15]. Thus, they concluded that the SBRT can be used as the first-line therapy for HCC patients with extensive PVTT originally considered unsuitable for surgical resection or transarterial chemoembolization. For such treatments, precise and accurate determination of the moving target is required to minimize doses for normal liver tissues, because HCC with PVTT is associated with worse Child-Pugh score [16].

For target delineation in radiotherapy treatment planning, Beddar et al. demonstrated that the CE-4D-CT allowed both enhancement of liver tumor (colorectal liver metastases, cholangiocarcinoma, and hepatocellular carcinoma) contrast and coverage over the entire breathing cycle, and they concluded that the CE-4D-CT might improve the accuracy of tumor contouring and localization [5]. With regard to the imaging of PVTT, several applications were applied such as ultrasonography (US) and magnetic resonance imaging (MRI) [17, 18]. Rossi et al. demonstrated that CE-US detected 100% of PVTT while CE-CT detected 68% of PVTT [17]. Kim et al. demonstrated that the gadoxetic acid–enhanced MRI (GA-MRI) provided good diagnostic performance in the detection of PVTT with sensitivities of approximately 90% [18]. For the detection of PVTT using the GA-MRI, Bae et al. reported that the additional information of diffusion- and T2-weighted imaging, which are not available with CECT, could contribute better depiction of common imaging findings, such as continuity with the tumor in the adjacent liver parenchyma than CE-CT [19], The study by Kim et al. demonstrated that the PVTT showed the increased T2 signal intensity and diffusion restriction, and the characteristic imaging features improved diagnostic capability [18]. Moreover, the diffusion-weighted imaging has advantage for distinguishing bland thrombus from neoplastic thrombus in the portal vein in patients with HCC [20]. Although the conventional CE-CT has been widely used for first-line diagnostic tests in patients suspected of having HCC, there is an apparent necessity for the improvement of image quality in CE-CT images. This study first implemented the CE-4D-DECT for PVTT and the imaging technique could provide VMIs at various energy level for the moving target. In this study, the VMI at 60 keV provided the highest CNR, resulting in higher subjective quantitative values than the S-VMI. Similar results were reported by Shuman et al. that the VMI at 50 keV showed greater CNR and higher subjective quantitative values for patients with HCC than the corresponding values of the VMI at 77 keV [21]. On the basis of conventional CE-4D-CT scans, Jensen et al. reported that there is non-negligible interobserver variability in HCC delineation in radiotherapy treatment planning, and they suggested the need for improving the image quality the CE-4D-CT [22]. The improvement of the image quality using the CE-4D-DECT may reduce the interobserver variability in PTVV delineation over the respiratory cycle in radiotherapy treatment planning.

Fernandes et al. assessed the liver tumor motion (hepatocellular carcinoma (n = 11), cholangiocarcinoma (n = 3), and liver metastasis (n = 2)) using the 4D-CT, and they observed the mean respiratory motion of 2.1, 4.8 8.0 mm in the L-R, A-P and S-I directions [23]. Our assessment of the respiratory motion of the PVTT yielded the similar results by Fernandes et al. that the respiratory motion was largest in the S-I direction. The motion of the PVTT was significantly smaller than the liver motion, which implied the motion of diaphragm could not well represent that of PVTT, especially in the L-R and A-P directions (Fig 5). Yang et al. reported that the tumor and diaphragm motions had high concordance when the distance between the tumor and tracked diaphragm area was small [24]. Because the distance between the diaphragm and PVTT is relatively large, the fiducial marker might be required to surrogate the PVTT when high radiation dose is delivered with a tight margin.

Several limitations of this study warrant mention. First, our data could not support all categories of the classification of PVTT (Vp1-Vp4) and various tumor sizes. A small PVTT can be easily missed by CT, which is unable to distinguish between tumor and thrombus tissues [17]. Second, CE-4D-DECT can be acquired at only one respiratory phase (40–80 s after the injection in this study) while diagnostic CT images are commonly acquired in four phases (pre-contrast, arterial, portal, and late). Finally, the objective and subjective image qualities between the O-VMI and the S-VMI were compared in this study, and the corresponding values of the conventional breath-hold polychromatic image (120 kVp) could not be assessed.

In conclusion, the VMI at 60 keV can be considered as the optimal image for radiotherapy treatment planning because that provided the highest CNR between the tumor and portal vein. Further, the optimal VMI significantly improved subjective image quality assessed by radiation oncologists. Because the respiratory motion of the diaphragm was significantly larger than that of the PVTT in the L-R and A-P directions, we need to be pay attention for localizing target in radiotherapy.

Data Availability

All relevant data are within the manuscript.

Funding Statement

This study was supported by JSPS KAKENHI Grant (Grant-in-Aid for Young Scientists 19K17285). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Yu J Il, Park HC. Radiotherapy as valid modality for hepatocellular carcinoma with portal vein tumor thrombosis. World J Gastroenterol 2016;22:6851–6863. 10.3748/wjg.v22.i30.6851 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Schöniger-Hekele M, Müller C, Kutilek M, Oesterreicher, C, Ferenci P, Gangl F. Hepatocellular carcinoma in Central Europe: prognostic features and survival. Gut 2001;48:103–109. 10.1136/gut.48.1.103 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Llovet JM, Bustamante J, Castells A, Vilana R, Ayuso MDC, Sala M, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: Rationale for the design and evaluation of therapeutic trials. Hepatology 1999;29:62–67. 10.1002/hep.510290145 [DOI] [PubMed] [Google Scholar]
  • 4.Choi BO, Choi IB, Jang HS, Kang YN, Jang JS, Bae SH, et al. Stereotactic body radiation therapy with or without transarterial chemoembolization for patients with primary hepatocellular carcinoma: Preliminary analysis. BMC Cancer 2008;8:1–8. 10.1186/1471-2407-8-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Beddar AS, Briere TM, Balter P, Pan T, Tolani N, Ng C, et al. 4D-CT imaging with synchronized intravenous contrast injection to improve delineation of liver tumors for treatment planning. Radiother Oncol 2008;87:445–448. 10.1016/j.radonc.2007.12.009 [DOI] [PubMed] [Google Scholar]
  • 6.Mileto A, Barina A, Marin D, Stinnett SS, Choudhury KR, Wilson JM, et al. Virtual Monochromatic Images from Dual-Energy Multidetector CT: Variance in CT Numbers from the Same Lesion between Single-Source Projection-based and Dual-Source Image-based Implementations. Radiology 2016;279:269–277. 10.1148/radiol.2015150919 [DOI] [PubMed] [Google Scholar]
  • 7.Matsumoto K, Jinzaki M, Tanami Y, Ueno A, Yamada M, Kuribayashi S. Virtual monochromatic spectral imaging with fast kilovoltage switching: improved image quality as compared with that obtained with conventional 120-kVp CT. Radiology 2011;259:257–262. 10.1148/radiol.11100978 [DOI] [PubMed] [Google Scholar]
  • 8.Husarik DB, Gordic S, Desbiolles L, Krauss B, Leschka S, Wildermuth S, et al. Advanced Virtual Monoenergetic Computed Tomography of Hyperattenuating and Hypoattenuating Liver Lesions Ex-Vivo and Patient Experience in Various Body Sizes. Invest Radiol 2015;50:695–702. 10.1097/RLI.0000000000000171 [DOI] [PubMed] [Google Scholar]
  • 9.The Liver Cancer Study Group of Japan. (2009) The general rules for the clinical and pathological study of primary liver cancer, ed 5. Tokyo, Kanehara. [Google Scholar]
  • 10.Ohira S, Wada K, Hirata T, Kanayama N, Ikawa T, Karino T, et al. Clinical implementation of contrast-enhanced four-dimensional dual-energy computed tomography for target delineation of pancreatic cancer. Radiother Oncol 2018;126:105–11. 10.1016/j.radonc.2018.01.012 [DOI] [PubMed] [Google Scholar]
  • 11.Zhang D, Li X, Liu B. Objective characterization of GE Discovery CT 750 HD scanner: Gemstone spectral imaging mode. Med Phys 2011;38:1178–1188. 10.1118/1.3551999 [DOI] [PubMed] [Google Scholar]
  • 12.Yagi M, Ueguchi T, Koizumi M, Ogata T, Yamada S, Takahashi Y, et al. Gemstone spectral imaging: Determination of CT to ED conversion curves for radiotherapy treatment planning. J Appl Clin Med Phys 2013;14:173–186. 10.1120/jacmp.v14i5.4335 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Kim TH, Kim DY, Park JW, Kim SH, Choi JI, Kim HB, et al. Dose-volumetric parameters predicting radiation-induced hepatic toxicity in unresectable hepatocellular carcinoma patients treated with three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 2007;67:225–231. 10.1016/j.ijrobp.2006.08.015 [DOI] [PubMed] [Google Scholar]
  • 14.Dawson LA, Normolle D, Balter JM, McGinn CJ, Lawrence TS, Ten Haken RK. Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys. 2002;53:810–21. 10.1016/s0360-3016(02)02846-8 [DOI] [PubMed] [Google Scholar]
  • 15.Shui Y, Yu W, Ren X, Guo Y, Xu J, Ma T, et al. Stereotactic body radiotherapy based treatment for hepatocellular carcinoma with extensive portal vein tumor thrombosis. Radiat Oncol 2018;13:188 10.1186/s13014-018-1136-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Connolly GC, Chen R, Hyrien O, Mantry P, Bozorgzadeh A, Abt P, et al. Incidence, risk factors and consequences of portal vein and systemic thromboses in hepatocellular carcinoma. Thromb Res 2008;122:299–306. 10.1016/j.thromres.2007.10.009 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Rossi S, Ghittoni G, Ravetta V, Viera FT, Rosa L, Serassi M, et al. Contrast-enhanced ultrasonography and spiral computed tomography in the detection and characterization of portal vein thrombosis complicating hepatocellular carcinoma. Eur Radiol 2008;18:1749–56. 10.1007/s00330-008-0931-z [DOI] [PubMed] [Google Scholar]
  • 18.Kim JH, Lee JM, Yoon JH, Lee DH, Lee KB, Han JK, et al. Portal vein thrombosis in patients with hepatocellular carcinoma: Diagnostic accuracy of gadoxetic acid–enhanced MR imaging. Radiology 2016;279:773–83. 10.1148/radiol.2015150124 [DOI] [PubMed] [Google Scholar]
  • 19.Bae JS, Lee JM, Yoon JH, Jang S, Chung JW, Lee KB, et al. How to best detect portal vein tumor thrombosis in patients with hepatocellular carcinoma meeting the Milan criteria: gadoxetic acid-enhanced MRI versus contrast-enhanced CT. Liver Cancer 2020;9:293–307. 10.1159/000505191 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Catalano OA, Choy G, Zhu A, Hahn PF, Sahani DV. Differentiation of malignant thrombus from bland thrombus of the portal vein in patients with hepatocellular carcinoma: application of diffusion-weighted MR imaging. Radiology 2010;254:154–62. 10.1148/radiol.09090304 [DOI] [PubMed] [Google Scholar]
  • 21.Shuman WP, Green DE, Busey JM, Mitsumori LM, Choi E, Koprowicz KM, et al. Dual-energy liver CT: Effect of monochromatic imaging on lesion detection, conspicuity, and contrast-to-noise ratio of hypervascular lesions on late arterial phase. Am J Roentgenol 2014;203:601–6. 10.2214/AJR.13.11337 [DOI] [PubMed] [Google Scholar]
  • 22.Jensen NKG, Mulder D, Lock M, Fisher B, Zener R, Beech B, et al. Dynamic contrast enhanced CT aiding gross tumor volume delineation of liver tumors: An interobserver variability study. Radiother Oncol 2014;111:153–7. 10.1016/j.radonc.2014.01.026 [DOI] [PubMed] [Google Scholar]
  • 23.Fernandes AT, Apisarnthanarax S, Yin L, Zou W, Rosen M, Plastaras JP, et al. Comparative assessment of liver tumor motion using cine-magnetic resonance imaging versus 4-dimensional computed tomography. Int J Radiat Oncol Biol Phys 2015;91:1034–40. 10.1016/j.ijrobp.2014.12.048 [DOI] [PubMed] [Google Scholar]
  • 24.Yang J, Cai J, Wang H, Chang Z, Czito BG, Bashir MR, et al. Is diaphragm motion a good surrogate for liver tumor motion? Int J Radiat Oncol Biol Phys 2014;90:952–8. 10.1016/j.ijrobp.2014.07.028 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Agostino Chiaravalloti

1 Sep 2020

PONE-D-19-33675

Improvement of image quality and assessment of respiratory motion for hepatocellular carcinoma with portal vein tumor thrombosis using contrast-enhanced four-dimensional dual-energy computed tomography

PLOS ONE

Dear Dr. Schingo Ohira,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by 30th september 2020. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Agostino Chiaravalloti, MD, PhD

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2.Thank you for including your ethics statement:  "This study was approved by our ethics committee, and written informed consent was obtained from each patient."

Please amend your current ethics statement to include the full name of the ethics committee/institutional review board(s) that approved your specific study.

Once you have amended this/these statement(s) in the Methods section of the manuscript, please add the same text to the “Ethics Statement” field of the submission form (via “Edit Submission”).

For additional information about PLOS ONE ethical requirements for human subjects research, please refer to http://journals.plos.org/plosone/s/submission-guidelines#loc-human-subjects-research.

3.Thank you for stating the following in the Acknowledgments Section of your manuscript:

[This study was supported by JSPS KAKENHI Grant (Grant-in-Aid for Young

Scientists 19K17285).]

We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:

 [The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.]

4. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. Please see the following video for instructions on linking an ORCID iD to your Editorial Manager account: https://www.youtube.com/watch?v=_xcclfuvtxQ

Additional Editor Comments (if provided):

Reviewers have now commented on your paper. You will see that they are advising that you revise in a minor way your manuscript.

If you are prepared to undertake the work required, I could reconsider my decision.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Overall, this research was well-designed. It suggested feasibility to used the CE-4D-DECT for better delineation of hepatocellular carcinoma with portal vein thrombosis. Authors have mentioned the limitation in phase of enhancement, which I agreed. Visibility of primary hepatocellular carcinoma and portal vein thrombosis is better in combined phases and the patterns of enhancement are various.

Movement of tumor correlated with diaphragm is also point of concerned. Authors point out the discordance between diaphragm and tumor movement.

I agreed but it would be better understand if authors would described more about how to measure tumor movement, eg.

The definition of GTV; Primary alone or combined with PVTT?

How to find the center of GTV? Was it contoured by radiation oncologist?

It would be appreciate if author have described it with figure, might be in supplement data.

In discussion, it would be outright if authors would add a paragraph mention about limitation of previously used or conventional technique in target delineation of hepatocellular carcinoma with some evidences.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2021 Jan 22;16(1):e0244079. doi: 10.1371/journal.pone.0244079.r002

Author response to Decision Letter 0


10 Sep 2020

Dear Editor and Reviewers,

We would like to thank you for the insightful comments on our paper. We have revised the manuscript in the light of the comments of the editor and reviewers. The revisions have been made using the 'Edit' function of Word. We hope that the revised version of our manuscript is now suitable for publication in the PLOS ONE.

Point-by-point responses according to the reviewers’ comments are as follows:

Editor’s Comments

Reviewers have now commented on your paper. You will see that they are advising that you revise in a minor way your manuscript.

If you are prepared to undertake the work required, I could reconsider my decision.

We have revised the manuscript in accordance with the reviewer’s comments. We hope that the revised version of our manuscript is now suitable for publication in the PLOS ONE.

Reviewer’s Comments

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Overall, this research was well-designed. It suggested feasibility to used the CE-4D-DECT for better delineation of hepatocellular carcinoma with portal vein thrombosis. Authors have mentioned the limitation in phase of enhancement, which I agreed. Visibility of primary hepatocellular carcinoma and portal vein thrombosis is better in combined phases and the patterns of enhancement are various. Movement of tumor correlated with diaphragm is also point of concerned. Authors point out the discordance between diaphragm and tumor movement.

Thank you so much for your favorable comments. We have revised the manuscript in accordance with the reviewer’s comments. We hope that the revised version of our manuscript is now suitable for publication in the PLOS ONE.

I agreed but it would be better understand if authors would described more about how to measure tumor movement, eg.

The definition of GTV; Primary alone or combined with PVTT?

How to find the center of GTV? Was it contoured by radiation oncologist?

It would be appreciate if author have described it with figure, might be in supplement data.

We agree the reviewer’s comments, and the additional Figure was described to explain the tumor/diaphragm motion measurement. The tumor and diaphragm were delineated by radiation oncologists and a medical physicist, respectively. Radiation oncologists determined the GTV as the PVTT alone or PVTT combined with the primary tumor. The center of the tumor was calculated by using a treatment planning system (Eclipse, Varian Medical Systems). We believe that the readers can understand the methodology of the tumor/diaphragm motion in the revised manuscript. Thank you for your insightful comments.

In discussion, it would be outright if authors would add a paragraph mention about limitation of previously used or conventional technique in target delineation of hepatocellular carcinoma with some evidences.

We agree the reviewer’s comment. Although the CE-CT has been widely used for first-line diagnostic tests in patients suspected of having HCC, many major guidelines (such as European Association for the Study of the Liver and American Association for the Study of Liver Diseases) now include gadoxetic acid-enhanced MRI (GA-MRI) as a first-line diagnostic test. The limitation of conventional CE-CT is that conventional CT can only depict PTVV in the HU values. For the detection of PVTT using the GA-MRI, Bae et al. reported that the additional information of diffusion- and T2-weighted imaging could contribute better depiction of common imaging findings, such as continuity with the tumor in the adjacent liver parenchyma than CE-CT [Bae et al., Liver Cancer, 2020]. Previous study Kim et al demonstrated that the PVTT showed the increased T2 signal intensity and diffusion restriction, and the characteristic imaging features improved diagnostic capability [Kim et al., Radiology, 2016]. Moreover, the diffusion-weighted imaging has advantage for distinguishing bland thrombus from neoplastic thrombus in the portal vein in patients with HCC [Catalano et al., Radiology, 2010]. The evidences in detecting PVTT using MR imaging are added in the paragraph mentioned about limitation of previously used or conventional technique.

Attachment

Submitted filename: Response to Reviewers.docx

Decision Letter 1

Dong-Hoon Lee

3 Dec 2020

Improvement of image quality and assessment of respiratory motion for hepatocellular carcinoma with portal vein tumor thrombosis using contrast-enhanced four-dimensional dual-energy computed tomography

PONE-D-19-33675R1

Dear Dr. Ohira,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Dong-Hoon Lee, Ph.D.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers have now commented on your paper. You will see that they are advising that you revise in a minor way your manuscript.

If you are prepared to undertake the work required, I could reconsider my decision.

Reviewers' comments:

Acceptance letter

Dong-Hoon Lee

22 Dec 2020

PONE-D-19-33675R1

Improvement of image quality and assessment of respiratory motion for hepatocellular carcinoma with portal vein tumor thrombosis using contrast-enhanced four-dimensional dual-energy computed tomography

Dear Dr. Ohira:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Prof. Dong-Hoon Lee

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    Attachment

    Submitted filename: Response to Reviewers.docx

    Data Availability Statement

    All relevant data are within the manuscript.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES